4 Questions for PCPs on Prevention and Management of Cardiometabolic Diseases

Semaglutide was associated with a significant reduction in risk for major adverse cardiovascular events after just 3 months of treatment in a population with established CVD.

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

EASL 2025. DA-1241 significantly reduced plasma ALT levels, improved systemic inflammatory and fibrosis biomarkers, according to drug developer MetaVia.